Literature DB >> 25209899

Injection of celiac disease patient sera or immunoglobulins to mice reproduces a condition mimicking early developing celiac disease.

Suvi Kalliokoski1, Sergio Caja, Rafael Frias, Kaija Laurila, Outi Koskinen, Onni Niemelä, Markku Mäki, Katri Kaukinen, Ilma R Korponay-Szabó, Katri Lindfors.   

Abstract

UNLABELLED: Typical features of celiac disease are small-bowel villus atrophy, crypt hyperplasia, and inflammation which develop gradually concomitant with ingestion of gluten. In addition, patients have anti-transglutaminase 2 (TG2) autoantibodies in their serum and tissues. The aim of this study was to establish whether celiac disease can be passively transferred to mice by serum or immunoglobulins. Serum aliquots or purified immunoglobulins (Ig) were intraperitoneally injected into Hsd:Athymic Nude-Foxn1nu mice for 8 or 27 days. As mice do not have proper IgA transport from peritoneum to blood, sera with a high content of IgG class anti-TG2 antibodies from untreated IgA-deficient celiac patients were used. Mouse sera were tested for celiac disease-specific autoantibodies, and several tissues were analyzed for autoantibody deposits targeted to TG2. Morphological assessment was made of the murine small intestinal mucosa. Injection of celiac disease patient sera or total IgG led to a significant delay in weight gain and mild diarrhea in a subset of mice. The mice injected with celiac patient sera or IgG had significantly decreased villus height crypt depth (Vh/CrD) ratios and celiac disease-specific autoantibody deposits targeted to TG2 in several tissues, including the small intestine. None of these features were observed in control mice. We conclude that administration of IgA-deficient celiac disease patient serum or total IgG induces both deterioration of the intestinal mucosa and clinical features of celiac disease in mice. The experimentally induced condition in the mice injected with patient serum or IgG resembles early developing celiac disease in humans. KEY MESSAGE: Celiac disease patient sera or total IgG was injected into athymic mice. A significant delay in weight gain and mild diarrhea was observed. Mice evinced significantly decreased villus height crypt depth ratios. Celiac disease-specific autoantibody deposits were present in several tissues. The condition in mice resembles early stage celiac disease in humans.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25209899     DOI: 10.1007/s00109-014-1204-8

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  38 in total

Review 1.  Coeliac disease--a diagnostic and therapeutic challenge.

Authors:  Katri Kaukinen; Katri Lindfors; Pekka Collin; Outi Koskinen; Markku Mäki
Journal:  Clin Chem Lab Med       Date:  2010-09       Impact factor: 3.694

2.  Identification of tissue transglutaminase as the autoantigen of celiac disease.

Authors:  W Dieterich; T Ehnis; M Bauer; P Donner; U Volta; E O Riecken; D Schuppan
Journal:  Nat Med       Date:  1997-07       Impact factor: 53.440

3.  Celiac disease and markers of celiac disease latency in patients with primary Sjögren's syndrome.

Authors:  S Iltanen; P Collin; M Korpela; K Holm; J Partanen; A Polvi; M Mäki
Journal:  Am J Gastroenterol       Date:  1999-04       Impact factor: 10.864

4.  Localization of cellular transglutaminase on the extracellular matrix after wounding: characteristics of the matrix bound enzyme.

Authors:  H F Upchurch; E Conway; M K Patterson; M D Maxwell
Journal:  J Cell Physiol       Date:  1991-12       Impact factor: 6.384

5.  Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura.

Authors:  W J HARRINGTON; V MINNICH; J W HOLLINGSWORTH; C V MOORE
Journal:  J Lab Clin Med       Date:  1951-07

6.  Humoral immune response to tissue transglutaminase is related to epithelial cell proliferation in celiac disease.

Authors:  Maria V Barone; Ivana Caputo; Maria T Ribecco; Maria Maglio; Roberto Marzari; Daniele Sblattero; Riccardo Troncone; Salvatore Auricchio; Carla Esposito
Journal:  Gastroenterology       Date:  2007-01-21       Impact factor: 22.682

Review 7.  Screening for coeliac disease in type 1 diabetes.

Authors:  G K T Holmes
Journal:  Arch Dis Child       Date:  2002-12       Impact factor: 3.791

8.  Diagnosing mild enteropathy celiac disease: a randomized, controlled clinical study.

Authors:  Kalle Kurppa; Pekka Collin; Mervi Viljamaa; Katri Haimila; Päivi Saavalainen; Jukka Partanen; Kaija Laurila; Heini Huhtala; Kaija Paasikivi; Markku Mäki; Katri Kaukinen
Journal:  Gastroenterology       Date:  2008-11-24       Impact factor: 22.682

Review 9.  IgA Fc receptors.

Authors:  Renato C Monteiro; Jan G J Van De Winkel
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

10.  Celiac Disease-Specific TG2-Targeted Autoantibodies Inhibit Angiogenesis Ex Vivo and In Vivo in Mice by Interfering with Endothelial Cell Dynamics.

Authors:  Suvi Kalliokoski; Ana-Marija Sulic; Ilma R Korponay-Szabó; Zsuzsa Szondy; Rafael Frias; Mileidys Alea Perez; Stefania Martucciello; Anne Roivainen; Lauri J Pelliniemi; Carla Esposito; Martin Griffin; Daniele Sblattero; Markku Mäki; Katri Kaukinen; Katri Lindfors; Sergio Caja
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

View more
  4 in total

Review 1.  Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.

Authors:  Stefania Martucciello; Gaetana Paolella; Carla Esposito; Marilena Lepretti; Ivana Caputo
Journal:  Cell Mol Life Sci       Date:  2018-08-22       Impact factor: 9.261

2.  Transglutaminase 2 in human diseases.

Authors:  Zsuzsa Szondy; Ilma Korponay-Szabó; Robert Király; Zsolt Sarang; Gregory J Tsay
Journal:  Biomedicine (Taipei)       Date:  2017-08-25

3.  Injection of prototypic celiac anti-transglutaminase 2 antibodies in mice does not cause enteropathy.

Authors:  Christian B Lindstad; M Fleur du Pré; Jorunn Stamnaes; Ludvig M Sollid
Journal:  PLoS One       Date:  2022-04-06       Impact factor: 3.240

Review 4.  Transglutaminase 2 and Transglutaminase 2 Autoantibodies in Celiac Disease: a Review.

Authors:  Tiina Rauhavirta; Minna Hietikko; Teea Salmi; Katri Lindfors
Journal:  Clin Rev Allergy Immunol       Date:  2019-08       Impact factor: 10.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.